Christophe Henry
About
Christophe Henry is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Christophe Henry has authored 25 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Christophe Henry's work include Chemical Synthesis and Analysis (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and HER2/EGFR in Cancer Research (6 papers). Christophe Henry is often cited by papers focused on Chemical Synthesis and Analysis (7 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and HER2/EGFR in Cancer Research (6 papers). Christophe Henry collaborates with scholars based in France, Belgium and Germany. Christophe Henry's co-authors include Yves Chapleur, Nicolas Moitessier, Roberta J. Ward, Robert R. Crichton, Bernard Maigret, Christophe Len, Marielle Chiron, Ying Zhang, Anne Florence and Parminder K. Mankoo and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and The Journal of Organic Chemistry.
In The Last Decade
Christophe Henry
24 papers receiving 448 citations
Peers
Christophe Henry
Kazumasa Hasegawa Japan
Benjamin F. Chu United States
Daniel J. Burdick United States
Ayşe Latif United Kingdom
Eva‐Laure Matera France
Tracey Colpitts United States
Alain Gast Switzerland
Francesca Civoli United States
Margaux Fresnais Germany
Rosanne M. Orr United Kingdom
Citations per year, relative to Christophe Henry Christophe Henry (= 1×)
peers
Kazumasa Hasegawa
Countries citing papers authored by Christophe Henry
Since
Specialization
Citations
This map shows the geographic impact of Christophe Henry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Henry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Henry more than expected).
Fields of papers citing papers by Christophe Henry
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Christophe Henry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Henry. The network helps show where Christophe Henry may publish in the future.
Co-authorship network of co-authors of Christophe Henry
This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Henry. A scholar is included among the top collaborators of Christophe Henry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Henry. Christophe Henry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lefebvre, Anne‐Marie, Julien Adam, Céline Nicolazzi, et al.. (2023). The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape. Lung Cancer. 184. 107356–107356.
2.
Gazzah, Anas, Philippe L. Bédard, Cinta Hierro, et al.. (2022). Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Annals of Oncology. 33(4). 416–425.
3.
Adam, Julien, Anne‐Marie Lefebvre, Céline Nicolazzi, et al.. (2021). 19P Therapeutic targets in non-small cell lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expression and its associated molecular landscape. Annals of Oncology. 32. S1381–S1381.
4.
El-Murr, Nizar, Sahar Kassem, Nadège Carrié, et al.. (2021). Abstract 1887: Anti-CD38/CD28xCD3 trispecific T cell engager induces proliferation of primary T cells and mediates potent killing of primary malignant plasma cells isolated from Multiple Myeloma bone marrow aspirates. Cancer Research. 81(13_Supplement). 1887–1887.
5.
El-Murr, Nizar, Christophe Henry, Elisa Francesconi, et al.. (2020). Abstract 5641: CD28 expression on multiple myeloma cells enhances the cytotoxic activity of CD38/CD28xCD3 trispecific T cell engager. Cancer Research. 80(16_Supplement). 5641–5641.
6.
Hahn, Friedrich, Corina Hutterer, Christophe Henry, et al.. (2018). Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity. Antiviral Research. 159. 84–94.
7.
Hutterer, Corina, Jens Milbradt, Stuart T. Hamilton, et al.. (2017). Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity. Antiviral Research. 143. 113–121.
8.
Stjepanovic, Neda, Min‐Hee Ryu, Josep Tabernero, et al.. (2016). First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848). European Journal of Cancer. 69. S14–S15.
9.
Bouchard, Hervé, François Clerc, Jidong Zhang, et al.. (2016). Abstract LB-053: Towards new cryptophycins as promising payloads for ADC. Cancer Research. 76(14_Supplement). LB–53.
10.
Henry, Christophe, Céline Nicolazzi, Céline Amara, et al.. (2015). Abstract B145: PK/PD evaluation of an anti-CEACAM5 antibody drug conjugate, in a colon patient-derived-xenografted mice model. Molecular Cancer Therapeutics. 14(12_Supplement_2). B145–B145.
11.
Chiron, Marielle, Rebecca G. Bagley, Jack Pollard, et al.. (2014). Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer. Molecular Cancer Therapeutics. 13(6). 1636–1644.
12.
Chiron, Marielle, Rebecca G. Bagley, Jack Pollard, et al.. (2013). Abstract B2: Switching to aflibercept treatment resulted in greater tumor responses than continuous bevacizumab treatment in patient-derived xenograft models of colorectal cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). B2–B2.
13.
Bozdağ, Murat, Tobias Dreker, Christophe Henry, et al.. (2012). Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(3). 715–719.
14.
Moitessier, Nicolas, Christophe Henry, Bernard Maigret, & Yves Chapleur. (2004). Combining Pharmacophore Search, Automated Docking, and Molecular Dynamics Simulations as a Novel Strategy for Flexible Docking. Proof of Concept: Docking of Arginine−Glycine−Aspartic Acid-like Compounds into the αvβ3 Binding Site. Journal of Medicinal Chemistry. 47(17). 4178–4187.
15.
Moitessier, Nicolas, et al.. (2003). On the Origin of the Facial Selectivity of the Sharpless Asymmetric Dihydroxylation of Styrene Derivatives. Journal of Carbohydrate Chemistry. 22(1). 25–34.
16.
Henry, Christophe, Nicolas Moitessier, & Yves Chapleur. (2002). Vitronectin Receptor -αVβ3 Integrin- Antagonists: Chemical and Structural Requirements for Activity and Selectivity. Mini-Reviews in Medicinal Chemistry. 2(6). 531–542.
17.
Moitessier, Nicolas, Christophe Henry, Christophe Len, & Yves Chapleur. (2002). Toward a Computational Tool Predicting the Stereochemical Outcome of Asymmetric Reactions. 1. Application to Sharpless Asymmetric Dihydroxylation. The Journal of Organic Chemistry. 67(21). 7275–7282.
18.
Henry, Christophe, Daniel Imbert, Fabrice Thomas, et al.. (2001). New 8-hydroxyquinoline and catecholate iron chelators: influence of their partition coefficient on their biological activity11Abbreviations: Kpart, partition coeffient; DFO, desferrioxamine B; TRX, O-Trensox; pFe = −log[Fe3+aq] at pH 7.4 with [Ligand] = 10 μM and [Fe] = 1 μM; LDH, lactate dehydrogenase; and PBS, phosphate-buffered saline.. Biochemical Pharmacology. 62(10). 1355–1362.
19.
Ward, Roberta J., Rachida Legssyer, Christophe Henry, & Robert R. Crichton. (2000). Does the haemosiderin iron core determine its potential for chelation and the development of iron-induced tissue damage?. Journal of Inorganic Biochemistry. 79(1-4). 311–317.
20.
Henry, Christophe, Isabelle Morel, Paul Baret, et al.. (1998). Iron Mobilisation and Cellular Protection by a New Synthetic Chelator O-Trensox. Biochemical Pharmacology. 55(11). 1797–1806.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kazumasa Hasegawa Breakdown of academic impact, for papers by Benjamin F. Chu Breakdown of academic impact, for papers by Daniel J. Burdick Breakdown of academic impact, for papers by Ayşe Latif Breakdown of academic impact, for papers by Eva‐Laure Matera Breakdown of academic impact, for papers by Tracey Colpitts Breakdown of academic impact, for papers by Alain Gast Breakdown of academic impact, for papers by Francesca Civoli Breakdown of academic impact, for papers by Margaux Fresnais Breakdown of academic impact, for papers by Rosanne M. Orr